dan 2163 has been researched along with Burning Mouth Syndrome in 3 studies
Burning Mouth Syndrome: A group of painful oral symptoms associated with a burning or similar sensation. There is usually a significant organic component with a degree of functional overlay; it is not limited to the psychophysiologic group of disorders.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Silvestre, FJ | 1 |
Silvestre-Rangil, J | 1 |
López-Jornet, P | 1 |
Hens, MJ | 1 |
Alonso-Ferreira, V | 1 |
Villaverde-Hueso, A | 1 |
Abaitua, I | 1 |
Posada de la Paz, M | 1 |
Maina, G | 1 |
Vitalucci, A | 1 |
Gandolfo, S | 1 |
Bogetto, F | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Prospective Study on the Treatment of Burning Mouth Syndrome With Integration of Traditional Chinese Medicine(TCM) and Western Medicine Based on TCM Syndrome Differentiation[NCT04189367] | Phase 3 | 80 participants (Anticipated) | Interventional | 2020-06-20 | Not yet recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for dan 2163 and Burning Mouth Syndrome
Article | Year |
---|---|
Burning mouth syndrome: a review and update.
Topics: Adult; Age Distribution; Aged; Algorithms; Amisulpride; Antidepressive Agents; Burning Mouth Syndrom | 2015 |
1 trial available for dan 2163 and Burning Mouth Syndrome
Article | Year |
---|---|
Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study.
Topics: Amisulpride; Antipsychotic Agents; Burning Mouth Syndrome; Humans; Male; Middle Aged; Paroxetine; Se | 2002 |
1 other study available for dan 2163 and Burning Mouth Syndrome
Article | Year |
---|---|
Cost-effectiveness analysis of burning mouth syndrome therapy.
Topics: Amisulpride; Antidepressive Agents; Burning Mouth Syndrome; Clonazepam; Cost-Benefit Analysis; Decis | 2012 |